Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2026 11:10 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention

Io Therapeutics reports publication of studies on its RXR agonist compound for prevention of Triple Negative Breast Cancer.
March 04, 2026 02:30 ET | Source: Tensive

Independent study presented at ECR highlights REGENERA™ bioresorbable scaffold potential for breast restoration after lumpectomy

Independent investigators from the University of Pisa presented new data at the 2026 European Congress of Radiology (ECR) Ultrasound follow-up documented predictable scaffold bioresorption and...
February 23, 2026 08:00 ET | Source: Artios Pharma

Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer

Artios receives FDA Fast Track designation for DNA polymerase theta (Polθ) inhibitor ART6043 for treatment of gBRCA-mutated HER2-negative breast cancer
January 30, 2026 08:15 ET | Source: ALX Oncology

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – -...
January 30, 2026 04:37 ET | Source: Research and Markets

Breast Cancer Liquid Biopsy Testing Devices Research Report 2026 - Global Market Size, Trends, Competitive Landscape, Opportunities, and Forecasts, 2021-2025 & 2025-2031

Dublin, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The "Breast Cancer Liquid Biopsy Testing Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...
January 22, 2026 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

STAFFORD, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
January 21, 2026 04:56 ET | Source: Research and Markets

Breast Cancer Imaging Market Size, Share & Trends Analysis Report 2025-2033 by Stage of Care (Diagnostic, Monitoring), End Use (Hospitals, Breast Care Centers), Technology and Region

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Breast Cancer Imaging Market Size, Share & Trends Analysis Report by Stage of Care (Diagnostic, Monitoring), End Use (Hospitals, Breast Care...
January 12, 2026 07:05 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer

Boehringer and Jazz Pharma partner to combine two unique HER2-targeted approaches, aiming to offer new breast cancer treatment options.
January 09, 2026 07:00 ET | Source: Athira Pharma, Inc.

Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”

Athira Pharma, Inc. today announced that it has changed its name to LeonaBio, Inc.
January 08, 2026 11:00 ET | Source: ALX Oncology

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel...